Tack, Véronique
Schuuring, Ed
Keppens, Cleo
Hart, Nils ‘t
Pauwels, Patrick
van Krieken, Han
Dequeker, Elisabeth M.C.
Article History
Received: 25 January 2018
Revised: 15 June 2018
Accepted: 9 July 2018
First Online: 24 August 2018
Competing interests
: Ed Schuuring, performed lectures for Illumina, Novartis, Pfizer and BioCartis; is a consultant in the advisory boards for AstraZeneca, Pfizer, Novartis and BioCartis, and received financial support from Roche, Biocartis, BMS and Pfizer (all fees to the Institution). The remaining authors declare no competing interests.
: All the authors will observe the terms of the Licence to Publish that they have signed or has been signed on their behalf and will seek the consent of the publishers acting for the owners of the journal, in any other circumstance.
: Ethical compliance is not applicable for this study. Informed consent is not a mandatory prerequisite for the use of patient-derived material, since samples for test validation are exempted from research regulations requiring informed consent.
: Data supporting the results can be obtained upon request.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).